Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system-Reference-Cited by-同舟云学术

Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system

Published:2012-08-09 Issue:8 Volume:36 Page:755-764
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Khan N.,Abbas A. M.,Bazzano L. A.,Koleva Y. N.¹,Krousel-Wood M.

Affiliation:

1. Southeast Louisiana Veterans Health Care System; New Orleans; LA; USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.12013/fullpdf

Reference42 articles.

1. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000;Loftus;Inflamm Bowel Dis,2007

2. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee;Kornbluth;Am J Gastroenterol,2010

3. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis;Kane;Am J Gastroenterol,2001

4. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis;Kane;Am J Med,2003

5. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease;Shale;Aliment Pharmacol Ther,2003

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An education‐based telehealth group improves the management and clinical outcomes of patients with inflammatory bowel disease in China (THEIM study);United European Gastroenterology Journal;2023-11-03

2. Impact of the COVID-19 Pandemic on the Lifestyle and Psychosocial Behavior of Patients with Inflammatory Bowel Diseases: A Narrative Review;Healthcare;2023-09-28

3. Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease;Advances in Therapy;2023-03-14

4. Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey;Inflammatory Intestinal Diseases;2023

5. Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction;Inflammatory Intestinal Diseases;2023